Current Role
  • Associate, Hagens Berman Sobol Shapiro LLP
  • Rachel’s practice focuses on pharmaceutical antitrust class-action litigation.
  • She is a core member of the team litigating In re Zetia (Ezetimibe) Antitrust Litigation, MDL No. 2836 (E.D. Va.), a federal antitrust lawsuit against Merck and Glenmark alleging the two unlawfully agreed to delay access to generic ezetimibe for years, resulting in billions in overcharges to purchasers.
  • Ms. Downey has also been instrumental in preparing settlement-related filings for and administering large class-action settlements. Most recently, she was part of the team securing a $483.85M settlement on behalf of the direct purchaser class in In re Glumetza Antitrust Litigation, the largest U.S. antitrust settlement in 2022.
Recent Cases
  • In re Zetia (Ezetimibe) Antitrust Litigation
  • Staley v. Gilead Sciences, Inc. (Gilead)
  • Government Employees Health Association v. Actelion Pharmaceuticals, Ltd. (Tracleer)
  • In re Glumetza Antitrust Litigation
Pro Bono
  • Volunteer Lawyers Project of the Boston Bar Association (VLP)
Personal Insight

For a month during her college years, Rachel lived in the Amazon.